News & Events

Minovia Therapeutics Announces Interim Data from Phase 2 Trial Download this news article Read More Read More

Minovia Therapeutics Announces FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in Pearson Syndrome Download this news article Read More Read More

June 25, 2025

Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Download this news article Read More Read More

April 3, 2025

Minovia Therapeutics Announces FDA Clearance of Second IND Download this news article Read More Read More

September 26, 2024

Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome Download this news article Read More Read More

January 5, 2023

Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member Download this news article Read More Read More

January 3, 2023

Minovia Therapeutics to Present at Biotech Showcase on J.P. Morgan Healthcare week Download this news article Read More Read More

December 21, 2022

Minovia Therapeutics Reports in Science Translational Medicine on First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial Diseases Download this news article Read More Read More

December 21, 2022

In a first, children with rare genetic diseases get mitochondrial transplants from their mothers Download this news article Read More Read More

February 28, 2022

The Israeli Company That Develops Treatment for Rare Diseases [Hebrew article] Download this news article Read More Read More